(Q36726204)

15 August 2017

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial (English)

1 reference

metastatic renal cell carcinoma

15 August 2017

phase II clinical trial

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ulka Vaishampayan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Kim Margolin

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Brian I Rini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

David F McDermott

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Bruce G Redman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Timothy M Kuzel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Michael R Harrison

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Harry A Drabkin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Saby George

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Theodore F Logan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Elizabeth R Plimack

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Alexandre M Lambert

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ian M Waxman

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Hans J Hammers

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

1 December 2014

1 reference

Journal of Clinical Oncology

15 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

1430-1437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

10 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Nivolumab plus ipilimumab in advanced melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Novel immunotherapeutic strategies in development for renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Cancer immunotherapy comes of age

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Cancer immunotherapy comes of age

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Molecular mechanisms of T-cell tolerance.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Tumor biology and prognostic factors in renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Cancer despite immunosurveillance: immunoselection and immunosubversion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Mechanisms of immune evasion by tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806782

Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25452452

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

NCCN clinical practice guidelines in oncology: kidney cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25452452

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2014.59.0703

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25452452%20AND%20SRC:MED&resulttype=core&format=json